Related Experiment Videos
Osteoporosis after solid organ and bone marrow transplantation
1College of Physicians & Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA.
Summary
Organ transplant recipients face significant bone loss and fracture risk due to immunosuppressive drugs. Early intervention is crucial for preventing and treating this unique osteoporosis.
Area of Science:
- Nephrology
- Hepatology
- Cardiology
- Pulmonology
- Endocrinology
- Orthopedics
Background:
- Organ transplantation is a common therapy for end-stage organ failure.
- The population of organ transplant survivors has grown significantly.
- Long-term complications, like osteoporosis, impact transplant recipients' quality of life.
Purpose of the Study:
- To review the clinical features of transplantation osteoporosis.
- To discuss the pathophysiology of post-transplantation bone loss.
- To outline prevention and therapy strategies for this condition.
Main Methods:
- Literature review of clinical features, pathophysiology, and treatment of transplantation osteoporosis.
- Analysis of bone loss mechanisms induced by immunosuppressive drugs.
- Examination of fracture incidence rates in transplant recipients.
Main Results:
- High-dose glucocorticoids and immunosuppressants (cyclosporine A, tacrolimus) cause rapid bone loss post-transplant.
- Fracture incidence rates range from 25-65% in affected patients.
- Bone loss primarily affects the spine and proximal femur.
Conclusions:
- Transplantation osteoporosis is a serious complication requiring targeted prevention and treatment.
- Strategies should address patients awaiting transplantation, in the early post-transplant period, and long-term survivors.
- Further research into optimal therapeutic interventions is warranted.